SCHEMBL8250876

SCHEMBL8250876

CC(C)CC(=O)Nc1ccc(CC(C)C)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.71
SMN1; SMN2 Q16637 4/20 0.67
RAB9A P51151 3/20 0.67
NPC1 O15118 2/20 0.67
HPGD P15428 2/20 0.63
LMNA P02545 2/20 0.63
MAPT P10636 2/20 0.56
MAPK1 P28482 1/20 0.56
GAA P10253 2/20 0.55
CRHBP P24387 1/20 0.55
CRHR2 Q13324 1/20 0.55
ALDH1A1 P00352 1/20 0.54
KDM4E B2RXH2 1/20 0.53
TSHR P16473 1/20 0.53
MTNR1B P49286 1/20 0.50
TRPV1 Q8NER1 2/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA4 P22748 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21765873 0.89 PTPN1 (0.88) PTPN1SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL24485239 0.87 RAB9A (0.79) PTPN1SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL13129132 0.87 PTPN1 (0.73) PTPN1SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL13024174 0.86 SMN1; SMN2 (0.55) PTPN1SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL8434001 0.86 SMN1; SMN2 (0.72) PTPN1SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL22162635 0.84 PTPN1 (0.59) PTPN1SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL19525769 0.84 PTPN1 (0.69) PTPN1SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL11209719 0.84 SMN1; SMN2 (0.54) PTPN1SMN1; SMN2RAB9ANPC1HPGD
SCHEMBL20715473 0.84 SMN1; SMN2 (0.54) PTPN1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL7282849 0.84 NPC1 (0.54) PTPN1SMN1; SMN2RAB9ANPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786122-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-31 US disclosed
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-04-10 US disclosed
US-7300936-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS APP, APBA1, BACE1 PTPN1 2775/4885SMN1; SMN2 675/4885RAB9A 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.